Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Access to AI-Enabled Drug Discovery Solutions: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Access to AI-Enabled Drug Discovery Solutions


Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, LLC (“Valo”), the technology company using human-centric data and computation powered by artificial intelligence (AI) to

QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021


QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year results of 2021 on Tuesday, February 8

VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis


Regulatory News:



Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Commission has approved Tavneos® in combination with a rituximab or cyclophosphamide regimen

QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its new QIAwave product line by launching three nucleic acid extraction kits that use fewer components and produce less waste

QIAGEN führt mit QIAwave umweltfreundliche Produktlinie ein
QIAGEN führt mit QIAwave umweltfreundliche Produktlinie ein


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung seiner neuen Produktlinie QIAwave und der ersten drei QIAwave Nukleinsäure-Extraktionskits bekannt. Diese neuen Kits

Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors


Regulatory News:



Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and PersonGen BioTherapeutics, a Chinese

PINC AI™ Launches INsights, an Enhanced Technology Offering for Customized, On-Demand Healthcare Analytics: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
PINC AI™ Launches INsights, an Enhanced Technology Offering for Customized, On-Demand Healthcare Analytics


PINC AI™, the technology and services platform of Premier, Inc (NASDAQ: PINC), today launched INsights, an enhanced self-service healthcare solution for the creation of customized, on-demand

CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005418/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



CSL

DGAP-News: Evotec und Lilly gehen Zusammenarbeit zur Erforschung von Wirkstoffen im Bereich Stoffwechselerkrankungen ein: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec und Lilly gehen Zusammenarbeit zur Erforschung von Wirkstoffen im Bereich Stoffwechselerkrankungen ein
DGAP-News: Evotec und Lilly gehen Zusammenarbeit zur Erforschung von Wirkstoffen im Bereich Stoffwechselerkrankungen ein
DGAP-News: Evotec and Lilly enter into drug discovery collaboration in metabolic diseases: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec and Lilly enter into drug discovery collaboration in metabolic diseases
DGAP-News: Evotec and Lilly enter into drug discovery collaboration in metabolic diseases
DGAP-News: Biotest AG: Biotest bekämpft Klimawandel durch CO2-neutrale Produktion: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest bekämpft Klimawandel durch CO2-neutrale Produktion
DGAP-News: Biotest AG: Biotest bekämpft Klimawandel durch CO2-neutrale Produktion
DGAP-News: Biotest AG: Biotest combats climate change through CO2-neutral production: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest combats climate change through CO2-neutral production
DGAP-News: Biotest AG: Biotest combats climate change through CO2-neutral production
Waters beschleunigt quantitative Massenspektrometrie mit neuer Anwendung auf der Informatikplattform waters_connect: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
Waters beschleunigt quantitative Massenspektrometrie mit neuer Anwendung auf der Informatikplattform waters_connect


ie Waters Corporation (NYSE:WAT) gab heute bekannt, dass sie ihre Informatik-Softwareplattform waters_connect™ erweitert, um Kunden bei der Analyse von Nahrungsmittel- und Umweltproben mit

Sensorion Updates on SENS-401 Phase 2 trial in Sudden Sensorineural Hearing Loss: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Updates on SENS-401 Phase 2 trial in Sudden Sensorineural Hearing Loss


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis


Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for

DGAP-Adhoc: RHÖN-KLINIKUM AG has reached an agreement with the State of Hesse on letter of intent on public investment subsidies: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
DGAP-Adhoc: RHÖN-KLINIKUM AG has reached an agreement with the State of Hesse on letter of intent on public investment subsidies
DGAP-Adhoc: RHÖN-KLINIKUM AG has reached an agreement with the State of Hesse on letter of intent on public investment subsidies
DGAP-Adhoc: RHÖN-KLINIKUM AG einigt sich mit dem Land Hessen über Absichtserklärung zu Investitionsfördermitteln: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
DGAP-Adhoc: RHÖN-KLINIKUM AG einigt sich mit dem Land Hessen über Absichtserklärung zu Investitionsfördermitteln
DGAP-Adhoc: RHÖN-KLINIKUM AG einigt sich mit dem Land Hessen über Absichtserklärung zu Investitionsfördermitteln
HAEMATO vertreibt PCR Point-of-Care Geräte zur wirkungsvollen Eindämmung des Corona-Pandemiegeschehenshttp://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png
HAEMATO vertreibt PCR Point-of-Care Geräte zur wirkungsvollen Eindämmung des Corona-Pandemiegeschehens
HAEMATO vertreibt PCR Point-of-Care Geräte zur wirkungsvollen Eindämmung des Corona-Pandemiegeschehens
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemichttp://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
Premier Inc.’s Contigo Health Expands Provider-Sponsored Health Plan Offerings Through New Partnership With OhioHealthy: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc.’s Contigo Health Expands Provider-Sponsored Health Plan Offerings Through New Partnership With OhioHealthy


Contigo Health LLC, a subsidiary of Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced a new partnership with OhioHealthy Plans, LLC

Agilent to Webcast First-Quarter Fiscal Year 2022 Financial Results Presentation:
Agilent to Webcast First-Quarter Fiscal Year 2022 Financial Results Presentation


Agilent Technologies Inc. (NYSE: A) will release first-quarter fiscal year 2022 financial results after the stock market closes on Tuesday, Feb. 22. The company will host a live webcast of its

Simulations Plus Enters New Collaboration with Leading Animal Health Company: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Enters New Collaboration with Leading Animal Health Company


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new

 Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights
 Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights


Regulatory News:



Lysogene (FR0013233475 – LYS) (Paris:LYS), a gene therapy platform company targeting central nervous system (CNS) diseases, today announced the termination of its license

Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for

Waters Accelerates Quantitative Mass Spectrometry With New Application on waters_connect Informatics Platform: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
Waters Accelerates Quantitative Mass Spectrometry With New Application on waters_connect Informatics Platform


Waters Corporation (NYSE:WAT) today announced it is expanding its waters_connect™ informatics software platform to support customers analyzing food and environmental samples with Waters’ tandem